Want to see JP:4889 full AI Analyst Report?

Renascience Inc. (4889) Price & Analysis

0 Followers

4889 Stock Chart & Stats

¥1436.00

-¥9.00(-2.89%)

At close: Jan 08 4:00 PM EST

¥1436.00

-¥9.00(-2.89%)

Day’s Range― - ―

52-Week Range¥1,108.00 - ¥3,310.00

Previous CloseN/A

Volume77.30K

Average Volume (3M)312.67K

Market Cap

¥20.65B

Enterprise Value¥18.70B

Total Cash (Recent Filing)¥3.40B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Aug 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-23.39

Shares Outstanding13,776,900

10 Day Avg. Volume205,420

30 Day Avg. Volume312,670

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)6.50

Price to Sales (P/S)315.22

P/FCF Ratio-74.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

De‑risked Capital StructureZero net debt is a durable structural strength: it reduces refinancing and interest-rate vulnerability, preserves strategic optionality for R&D or partnering, and lengthens runway versus peers reliant on external funding, improving resilience over the next several quarters.

High Gross MarginsConsistently very high gross margins indicate structural product economics that can support profitability at scale. If the company stabilizes revenue and controls operating costs, high gross margins provide durable upside to operating leverage and long‑term margin sustainability.

Equity Growth Supporting AssetsGrowing equity suggests the firm has increased its capital base without adding leverage, enabling investment in assets or programs without raising debt. This strengthens financing flexibility and supports medium‑term execution if cash burn and revenue trends improve.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flows are a durable risk: they erode cash reserves and make the company reliant on external funding or equity dilution. Over 2–6 months this limits investment capacity and raises uncertainty about sustaining programs without new capital.

Sharp Revenue DeclineA material recent revenue decline signals structural demand or execution issues rather than transitory noise. Persistent top‑line weakness undermines operating leverage, makes margin recovery harder, and reduces the likelihood that high gross margins will translate into durable profits in the near term.

Structural Unprofitability & Earnings VolatilityRepeated operating losses and volatile earnings quality show the business currently cannot convert margins into sustainable net returns. This weakens return on invested capital and complicates reinvestment planning, creating a persistent risk to shareholder value absent a clear path to profitability.

4889 FAQ

What was Renascience Inc.’s price range in the past 12 months?

Renascience Inc. lowest stock price was ¥1108.00 and its highest was ¥3310.00 in the past 12 months.

What is Renascience Inc.’s market cap?

Renascience Inc.’s market cap is ¥20.65B.

When is Renascience Inc.’s upcoming earnings report date?

Renascience Inc.’s upcoming earnings report date is Aug 14, 2026 which is in 20 days.

How were Renascience Inc.’s earnings last quarter?

Renascience Inc. released its earnings results on May 13, 2026. The company reported -¥6.24 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.24.

Is Renascience Inc. overvalued?

According to Wall Street analysts Renascience Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renascience Inc. pay dividends?

Renascience Inc. does not currently pay dividends.

What is Renascience Inc.’s EPS estimate?

Renascience Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renascience Inc. have?

Renascience Inc. has 13,776,900 shares outstanding.

What happened to Renascience Inc.’s price movement after its last earnings report?

Renascience Inc. reported an EPS of -¥6.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 26.762%.

Which hedge fund is a major shareholder of Renascience Inc.?

Currently, no hedge funds are holding shares in JP:4889

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renascience Inc.

Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.